Business
Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders
Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders
About this update from Jaguar Health, Inc.
[{"type":"text","content":"Crofelemer delayed-release tablets are Jaguar's FDA-approved prescription drug under botanical guidance (\"botanical drug\") derived from the Croton lechleri tree. Crofelemer, in a novel liquid formulation, is being developed as the potential first oral adjunctive therapy for Intestinal Failure (IF) from microvillus inclusion disease (MVID) and short bowel syndrome (SBS)Crofelemer development with novel formulations for different gastrointestinal disorders reflects a differentiated botanical drug platform integrating ethnobotanical medicine, sustainable harvesting, complex CMC, and novel bioassays to support approval under FDA botanical guidanceTraditional knowledge of Croton lechleri use supported ethnobotanical research that led to development and approval of crofelemer, whose first in class anti-secretory mechanism was characterized through modern pharmacology and mechanism-based bioassays. Recent milestones include continued evaluation in an extension phase for Jaguar family company Napo's pivotal clinical trial of crofelemer as adjunctive therapy to Parenteral Support (PS) for MVID and upcoming ESPGHAN presentations in pediatric MVID and SBS-IF patientsFDA approval of crofelemer as an oral botanical drug highlights the totality-of-evidence and creates a significant practical barrier to generic replication SAN FRANCISCO, CA / ACCESS Newswire / May 28, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) and family company Napo Pharmaceuticals (Napo) today highlighted how the Company's long-standing research in ethnobotanical medicine, sustainable harvesting, and regulatory drug development under botanical guidance (\"botanical drug\") continues to inform the development of crofelemer as a novel oral adjunctive therapy to PS for rare congenital gastrointestinal intestinal failure (IF) disorders, including microvillus inclusion disease (MVID) and short bowel syndrome (SBS).It has been through direct research collaboration with indigenous experts on plant and ethnobotanical medicine that Napo team members learned about the use of extracts of Croton lechleri to treat a number of gastrointestinal conditions. We have had cross-cultural medical discussions with traditional healers - a methodology that provides an opportunity to elucidate new ways of treating unmet medical needs such as IF. Napo has been collaborating on the long term ...